These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2646056)

  • 21. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
    Del Favero A; Menichetti F
    Eur J Cancer; 1993; 29A Suppl 1():S2-6. PubMed ID: 8427721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of the febrile neutropenic patient.
    Picazo JJ;
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients.
    Klastersky J
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):201S-207S. PubMed ID: 2686921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protecting neutropenic patients from bowel-derived organisms.
    Warren RE
    J Hosp Infect; 1991 Sep; 19 Suppl C():43-58. PubMed ID: 1684195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
    Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S
    Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of infections in granulocytopenic patients by fluorinated quinolones.
    Rozenberg-Arska M; Dekker AW; Verhoef J
    Recent Results Cancer Res; 1991; 121():337-46. PubMed ID: 1857872
    [No Abstract]   [Full Text] [Related]  

  • 27. Quinolone therapy in the management of infection after irradiation.
    Brook I; Ledney GD
    Crit Rev Microbiol; 1992; 18(4):235-46. PubMed ID: 1524673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy of infections in cancer patients: a review.
    Sim SK
    Am J Hosp Pharm; 1975 Jan; 32(1):35-44. PubMed ID: 1092159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients.
    Rolston KV; Bodey GP; Elting L
    Am J Med; 1990 Mar; 88(3C):24S-29S; discussion 38S-42S. PubMed ID: 2180294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empirical antimicrobial therapy in the neutropenic host.
    Young LS
    N Engl J Med; 1986 Aug; 315(9):580-1. PubMed ID: 3526156
    [No Abstract]   [Full Text] [Related]  

  • 31. [Bacterial sepsis in the hematologic neutropenic patient].
    Todeschini G; Benato G; Carlini S; Veneri D
    Haematologica; 1989 Oct; 74(5 Suppl):297-309. PubMed ID: 2480272
    [No Abstract]   [Full Text] [Related]  

  • 32. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study.
    Cruciani M; Concia E; Navarra A; Perversi L; Bonetti F; Aricò M; Nespoli L
    Infection; 1989; 17(2):65-9. PubMed ID: 2654019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
    J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
    Bow EJ; Mandell LA; Louie TJ; Feld R; Palmer M; Zee B; Pater J
    Ann Intern Med; 1996 Aug; 125(3):183-90. PubMed ID: 8686975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial prophylaxis in the neutropenic host: lessons of the past and perspectives for the future.
    Young LS
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):93-7. PubMed ID: 3132393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combating infections in neutropenic patients.
    Pizzo PA
    Hosp Pract (Off Ed); 1989 Jul; 24(7):93-100, 103-4, 107-10. PubMed ID: 2501330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
    Mori S; Ohashi K; Akiyama H; Shoji H; Sato H; Tanikawa S; Sakamaki H; Onozawa Y
    Kansenshogaku Zasshi; 1994 Jul; 68(7):872-8. PubMed ID: 8089554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of fluoroquinolones as prophylactic agents in patients with neutropenia.
    Patrick CC
    Pediatr Infect Dis J; 1997 Jan; 16(1):135-9; discussion 160-2. PubMed ID: 9002124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of bacterial infections using ciprofloxacin in granulocytopenic patients with cancer].
    Snoeck R; Gerain J; Leleux A; Libert J; Meunier F
    Rev Med Brux; 1989 Dec; 10(10):408-13. PubMed ID: 2602729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of infections in the neutropenic patient.
    Verhoef J
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S359-67. PubMed ID: 8274601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.